Moshe Rozenbaum was named Chief Executive Officer of Nano Dimension Ltd., effective November 3, 2026. As of November 6, 2026, Nano Dimension Ltd. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from July 21, 2026 to November 5, 2026, naming 1 appointment (Form 8-K, November 5, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Nano Dimension Ltd? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Nano Dimension Ltd. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-07-21 to 2026-11-05. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Nano Dimension Ltd. files it.
Also on the record for Nano Dimension Ltd.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 29, 2026 | Stake report, Schedule 13D/A, by Murchinson Ltd. | 10.1% of the class | 5%+ stakes | Source |
| August 21, 2026 | Stake report, Schedule 13G, by TANG CAPITAL MANAGEMENT, LLC | 9.1% of the class | 5%+ stakes | Source |
| July 27, 2026 | Stake report, Schedule 13D/A, by TANG CAPITAL MANAGEMENT, LLC | 7.9% of the class | 5%+ stakes | Source |
| July 22, 2026 | Stake report, Schedule 13D/A, by Oramed Pharmaceuticals Inc. | 3.3% of the class | 5%+ stakes | Source |
| July 20, 2026 | Stake report, Schedule 13D/A, by Murchinson Ltd. | 8.1% of the class | 5%+ stakes | Source |
| June 30, 2026 | Stake report, Schedule 13D, by TANG CAPITAL MANAGEMENT, LLC | 6.8% of the class | 5%+ stakes | Source |
| June 23, 2026 | Stake report, Schedule 13D/A, by Murchinson Ltd. | 9.6% of the class | 5%+ stakes | Source |
| June 17, 2026 | Stake report, Schedule 13D/A, by Oramed Pharmaceuticals Inc. | 7.2% of the class | 5%+ stakes | Source |
| May 21, 2026 | Stake report, Schedule 13D/A, by Murchinson Ltd. | 7.4% of the class | 5%+ stakes | Source |
| February 19, 2026 | Stake report, Schedule 13D/A, by Oramed Pharmaceuticals Inc. | 5.2% of the class | 5%+ stakes | Source |
| January 29, 2026 | Stake report, Schedule 13D, by Oramed Pharmaceuticals Inc. | 5% of the class | 5%+ stakes | Source |
| July 14, 2025 | Stake report, Schedule 13D/A, by Anson Funds Management LP | 4.2% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Nano Dimension Ltd. now and the warning signs.
Free to see. No signup.
Keep reading
More on Nano Dimension Ltd. and the records around it.
Nano Dimension Ltd. elsewhere on the record
- 5%+ stake filings Oct 2026
- Who owns it
Companies that share a holder
- Murchinson Ltd. also filed stake reports on 2 other companies: Valion Bio, Inc. (Jul 2026), Pelthos Therapeutics Inc. (Nov 2025)
- Oramed Pharmaceuticals Inc. also filed stake reports on 2 other companies: Lifeward Ltd. (May 2026), Scilex Holding Co (Feb 2026)
- TANG CAPITAL MANAGEMENT, LLC also filed stake reports on 33 other companies: EyePoint, Inc. (Oct 2026), Skye Bioscience, Inc. (Oct 2026), Capricor Therapeutics, Inc. (Aug 2026)
Watch Nano Dimension Ltd.
Get an email when Nano Dimension Ltd. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Nano Dimension Ltd.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Nano Dimension Ltd.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Nano Dimension Ltd. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 13 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-11-05 | In | Chief Executive Officer | 2026-11-03 | 8-K, 2026-11-05 | |
| 2026-07-21 | Reported | not named in the filing | 8-K, 2026-07-21 |
Who leads Nano Dimension Ltd., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Executive Officer: Moshe Rozenbaum, appointed, effective 2026-11-03 (filed 2026-11-05).
New leaders reset buying decisions — get the Full Report on Nano Dimension Ltd.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Executive Officer at Nano Dimension Ltd., with the record behind each one.
Find candidates like Chief Executive Officer at Nano Dimension Ltd.Every change, in the filing's words
Appointed: Moshe Rozenbaum, Chief Executive Officer, effective 2026-11-03
(c) Appointment of Certain Officers On November 3, 2026, the Board of Directors (the "Board") of the Company appointed Moshe Rozenbaum, who had been serving as the Company's Interim Chief Executive Officer since July 21, 2026, to serve as the Company's permanent Chief Executive Officer, effective as of November 3, 2026 (the "Effective Date").
- Mr. Rozenbaum will also continue to serve as a member of the Board of Directors.
- (e) Compensatory Arrangements of Certain Officers In connection with Mr. Rozenbaum's transition to permanent Chief Executive Officer, the Company and Mr. Rozenbaum entered into an Employment Agreement (the "Agreement") effective as of November 3, 2026: Annual base salary of US$600,000; A new-hire equity award of 1,000,000 RSUs, vesting over three years in three equal annual installments (approximately 33.3% on each anniversary of the applicable vesting commencement date), subject to the terms of the applicable equity incentive plan and award agreement.
Reported
(b) Resignation of Chief Executive Officer and Directors In connection with the execution of the Agreement, on July 17, 2026, the Departing Directors submitted irrevocable resignations from the Board and all positions with the Company and its subsidiaries, effective immediately following execution of the Agreement.
- The resignations of the Departing Directors were not due to any disagreement with the Company or any matter relating to the Company's operations, policies or practices.
- In addition, Mr. Stehlin resigned as the Chief Executive Officer of the Company ("CEO"), effective immediately following execution of the Agreement.
- (c) Appointment of Interim Chief Executive Officer On July 21, 2026, Mr. Rozenbaum was appointed as the Interim CEO of the Company.
- Mr. Rozenbaum, age 44, has many years of experience as a strategic business leader with deep expertise in financial markets, capital raising, and corporate development.
- From May 2023 to August 2025, Mr. Rozenbaum served as the VP - Corporate Development of the Company.
- Mr. Rozenbaum has served as an external director and Chairman of the Audit Committee of Lifeward Ltd. (Nasdaq: LFWD) since March 2026.
- Prior to that, from January 2019 to June 2022, Mr. Rozenbaum served as the Head of Business Development for Yedid Capital Management Inc., and from 2011 to 2019, served as the Chief Financial Officer and Chief Operating Officer of Fluent Trade Technologies Ltd. and previously served as a Senior Accountant at Ernst & Young.
- Mr. Rozenbaum holds a B.A. in accounting from Touro University and is a Certified Public Accountant.
- The Company will enter into its standard form of indemnification agreement with Mr. Rozenbaum.
Tools for this story
Each opens in a new tab, filled in for Nano Dimension Ltd.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.